Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00529438 · ClinicalTrials.gov registry record · Phase 1
RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT00529438 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 47 participants.
The verdict
NCT00529438, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
This study assesses the tolerability, safety, efficacy and pharmacokinetics of Bardoxolone methyl (RTA 402) in advanced solid tumors and lymphoid malignancies.
Interventions
- DRUG Bardoxolone methyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2006-04-30 |
| Est. Completion | 2008-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00529438
The ClinicalTrials.gov registry entry for NCT00529438 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bardoxolone methyl is the first listed.
NCT00529438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00529438 about?
NCT00529438 is a clinical study titled "RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies". This study assesses the tolerability, safety, efficacy and pharmacokinetics of Bardoxolone methyl (RTA 402) in advanced solid tumors and lymphoid malignancies.
What is the current status of trial NCT00529438?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2006-04-30. Estimated completion is 2008-12-01.
What interventions are being tested in trial NCT00529438?
The interventions under investigation include: Bardoxolone methyl (DRUG).
Who is sponsoring clinical trial NCT00529438?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.